NEW DELHI – The Union Ministry of Health and Family Welfare, in collaboration with leading clinical research institutions, inaugurated a high-level National Conference on Rare Diseases this week in the capital. The two-day summit has brought together geneticists, policymakers, patient advocacy groups, and pharmaceutical innovators to address the critical challenges of affordability, late-stage diagnosis, and the development of “orphan drugs” within the Indian healthcare framework.
Addressing the Diagnostic Gap
One of the central themes of the conference is the urgent need for early and accurate diagnosis. In India, a patient suffering from a rare disease often undergoes a “diagnostic odyssey,” consulting an average of seven to eight physicians over a span of five years before receiving a definitive diagnosis. Experts at the summit highlighted that nearly 80% of rare diseases are genetic in origin, yet many remain undetected due to a lack of awareness at the primary healthcare level and limited access to advanced genomic sequencing.
To combat this, the government outlined plans to expand the network of Centres of Excellence (CoEs). These specialized hubs are being equipped with cutting-edge molecular diagnostic tools to ensure that infants and young children are screened earlier, allowing for interventions that can significantly alter the disease trajectory.
Innovation and Indigenous Drug Development
A major hurdle in the treatment of rare diseases is the exorbitant cost of specialized medications, often referred to as orphan drugs. Currently, most of these treatments are imported, making them inaccessible to the vast majority of the population. The conference emphasized a shift toward innovation and self-reliance.
Government representatives discussed the implementation of the National Policy for Rare Diseases, which has seen an increase in one-time financial assistance for patients. However, the focus is now moving toward long-term sustainability. Discussions are underway to incentivize domestic pharmaceutical companies to invest in R&D for rare conditions through “priority review” status and tax exemptions. By fostering a domestic manufacturing ecosystem, the ministry aims to reduce the cost of treatment by up to 60–70% for specific metabolic disorders and rare blood conditions.
Public-Private Partnerships and Crowdfunding
Recognizing that the government cannot bridge the funding gap alone, the summit explored the role of Public-Private Partnerships (PPPs) and digital crowdfunding. A dedicated portal launched under the National Policy is being revamped to connect individual donors and corporate social responsibility (CSR) initiatives directly with verified patient needs.
Furthermore, clinical experts called for the creation of a National Rare Disease Registry. A comprehensive database would provide researchers with the necessary epidemiological data to understand the prevalence of specific conditions in India, which is essential for attracting global clinical trials and developing targeted therapies suited for the Indian genetic makeup.
A Patient-Centric Approach
The conference also served as a platform for patient advocates who stressed that “rare is not invisible.” Discussions covered the need for holistic care, including rehabilitative services, psychological support for families, and inclusive education for children living with chronic conditions.
As the summit concludes, a roadmap is expected to be finalized, focusing on integrating rare disease management into the broader Ayushman Bharat framework. This integration would ensure that the most vulnerable sections of society are not left behind in the pursuit of specialized medical care, marking a new chapter in India’s journey toward universal health coverage.
